Angiotensin-converting enzyme inhibitors combined with higher doses of hydrochlorothiazide (HCT), that is, 25 mg daily, have been recognized as an effective form of antihypertensive therapy. To evaluate the coadministration of 20 mg ramipril with 25 mg HCT, we carried out a randomized, double-blind, controlled trial with two dose schedules of ramipril (20 mg q.d. and 10 mg b.i.d.) and HCT monotherapy arms as comparators in 354 patients with stage 2 hypertension. The clinic blood pressure (BP) was assessed using a semiautomatic digital device and 24-h BP was measured using ambulatory BP recordings at baseline and after 8 weeks of therapy. At baseline, the demographics and baseline BP values were similar in the four treatment groups (age: 51-53 years, 52-58% male, 64-68% non-black, clinic BP: 155-158/103-104 mm Hg). Ramipril-HCT induced significantly greater reductions in both the clinic and ambulatory BP than the HCT and ramipril monotherapy treatments (for example, additional reductions in ambulatory BP on ramipril-HCT ranged from À7.3/À5.2 to À10.3/À7.4 mm Hg compared to the monotherapies, all Po0.001). Reductions from baseline were still numerically greater for the clinic BPs derived from device measurements than those for the BP values derived from 24-h ambulatory BP measurements (changes in clinic diastolic BP ranged from À8.5 to À15.5 mm Hg across treatment groups, whereas changes in ambulatory diastolic BP were À4.7 to À12.0 mm Hg for the same groups). Thus, these data support the use of ambulatory BP monitoring even when automated BP devices are used for the assessment of clinical BP in trials that attempt to differentiate BP responses among active comparator groups. In conclusion, based on its efficacy and tolerability profile the combination of ramipril and HCT was shown to be effective therapy for the treatment of stage 2 hypertension.
Introduction
To produce the maximum reduction in clinical cardiovascular events, it is widely accepted that improvement in blood pressure (BP) control is required. 1, 2 Expert consensus guidelines advocate BP levels o140/90 mm Hg in patients lacking target organ involvement, o130/80 mm Hg in patients with diabetes, heart and kidney disease and o120/ 80 mm Hg for patients with left ventricular dysfunction. 3, 4 During the past decade, the use of blockers of the renin-angiotensin system alone or in fixed combinations with low-dose (12.5 mg) hydrochlorothiazide (HCT) has become a popular strategy in the management of hypertension. This is not surprising, as inhibitors of the renin-angiotensin system are not only effective in reducing BP but also have excellent tolerability profiles. 5, 6 Furthermore, clinical trials have shown that the angiotensinconverting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce cardiovascular events, reduce the proportion of hypertensive patients who develop type II diabetes mellitus and prolong survival in such conditions as high-risk hypertension, 7 vascular disease, 8 heart failure 9 and diabetic nephropathy. 10, 11 Use of higher doses of thiazide diuretics (that is, 25 mg total daily dose) in combination with other antihypertensive drugs has become recognized as a safe and effective strategy to improve BP control. 12 Evaluation of fixed-dose combinations of ACE inhibitors with 25 mg HCT is needed to determine the benefits and side effects of these therapies as they are developed.
We assessed the combination of 20 mg ramipril with 25 mg HCT by performing a randomized, double-blind trial evaluating the combination versus the monotherapy components. Owing to concerns related to reproducibility of standard clinic BP measurements observed in many clinical trials of antihypertensive therapies, 13, 14 we incorporated semiautomatic devices for clinical measurements and 24-h ambulatory monitoring for whole-day BP assessments into the study. Furthermore, the US Food and Drug Administration (FDA) requested the addition of a 10 mg ramipril twice daily (b.i.d.) arm to compare its antihypertensive efficacy to both the 20 mg ramipril once daily (q.d.) arm and the combination therapy group.
Methods

Study design
This trial was a multicentre, randomized, doubleblind, double-dummy, parallel-arm study evaluating the effects of a dose combination of 20 mg ramipril and 25 mg HCT (coadministered once daily) versus 20 mg ramipril q.d., 10 mg ramipril b.i.d. and 25 mg HCT q.d. in subjects with stage 2 essential hypertension. The randomization was 2:1:1:2, respectively.
The primary objective of the study was to determine whether 20/25 mg ramipril/HCT administered once daily was superior to 20 mg ramipril alone administered once daily and to 25 mg HCT alone administered once daily for the control of the diastolic BP (DBP) following 8 weeks of treatment.
Patients completed a single-blind, placebo run-in/ antihypertensive drug washout (if applicable) period of up to 4 weeks to establish baseline BP values. Eligible patients were randomized to double-blind, double-dummy treatment of 10 mg ramipril, 12.5 mg HCT or 10 mg ramipril with 12.5 mg HCT (ramipril-HCT) administered once each morning and placebo in the evening. After 2 weeks, patients returned to the clinic and were up-titrated to 20 mg ramipril q.d. with evening placebo, 10 mg ramipril b.i.d. (morning and evening), 25 mg HCT q.d. with evening placebo or 20/25 mg ramipril-HCT q.d. with evening placebo depending upon their initial randomized treatment arm. Starting at the up-titration visit and at 2-week intervals thereafter for a total of an additional 6 weeks, study patients were examined in the clinic between 0700 and 1000 hours for clinical evaluation (typically 22-24 h following the morning dose of study drug and 10-12 h following the evening dose of study drug). At every visit, adverse events were also assessed by non-leading questions.
Patient population
Men and women with stage 2 hypertension were included in the study if their average seated DBP was between 100 and 115 mm Hg (inclusive) and if the average seated systolic BP (SBP) was between 140 and 180 mm Hg (inclusive) at the end of the single-blind, placebo run-in period. The difference in DBP between the last two prerandomization visits had to be o10 mm Hg. Major exclusion criteria were stroke or myocardial infarction within the past 3 years, congestive heart failure, known or suspected secondary hypertension, clinically relevant conduction and rhythm disturbances, and significant renal (estimated glomerular filtration rate o40 ml min À1 ) or hepatic disease (serum transaminases 42 times the upper limits of normal).
Measurements of efficacy and safety parameters
Clinic BP measurements were obtained at every visit using an Omron HEM-907 digital BP monitor (Omron Healthcare, Vernon Hills, IL, USA) in triplicate after 5 min in the seated position followed by a single measurement after standing for 1 min. BP measurements were made at 2-min intervals while seated. The pulse rate was measured in conjunction with the BP measurements at each visit. Ambulatory BP monitoring (ABPM) was performed using a Spacelabs model 90207 recorder (Spacelabs Inc., Redmond, WA, USA) during the 24-h period before randomization and the 24-h period before the final treatment visit (after 8 weeks of therapy). The BP and heart rate measurements were obtained every 15 min between 0600 and 2200 hours (daytime, awake period) and every 20 min between 2200 and 0600 hours (nighttime, sleep period). Patients were instructed to be awake at least 2 h before returning for device removal.
The 24-h ABPM procedure began at 0800 hours±2 h on a normal workday. In order for the 24-h test to be considered successful, at least 80% of total readings for the 24-h period had to be valid, and no more than 2 consecutive hours were allowed to lack valid readings. An hour was considered valid if at least one valid reading was captured during that hour. Patients who did not have a successful ABPM at baseline were offered the opportunity to repeat the 24-h procedure. Each patient's mean 24-h ABPM SBP and DBP were calculated by averaging the valid readings over each 24-h period. Values beyond the first 24 h were truncated. Safety was assessed by the incidence, intensity and seriousness of adverse events, vital sign assessments and changes from baseline to the end of the study in laboratory and electrocardiographic parameters. All reported adverse events were categorized by body system and preferred term using the Medical Dictionary for Regulatory Activities (Med-DRA). 15 The incidence of treatment-emergent adverse effects in each treatment group was tabulated by intensity and by relationship to study drug (as ascertained by the site study personnel). Treatment compliance was assessed by a physical count of returned study medications.
Statistical analyses
The primary end point for assessing efficacy was the change from baseline to the end-of-study visit in clinic DBP measured 22-24 h after the morning dose of study drug and 10-12 h following the evening dose of study drug. In the case of patients withdrawing from the study before the completion of the 8-week treatment period, a last-observation-carriedforward imputation was performed. All analyses were performed on the primary end point and all testing on secondary end points were performed at a two-sided a ¼ 0.05. All statistical testing was performed on the intent-to-treat efficacy population that included all patients who had baseline BP measurements, received at least one dose of doubleblind study drug during the randomized treatment period and had at least one post-baseline BP measurement.
The primary objective of the study was to show that ramipril-HCT was superior to ramipril alone and HCT alone. The sample size calculation assumed a common standard deviation of 8 mm Hg. For the ramipril-HCT, HCT, 20 mg ramipril q.d. and 10 mg ramipril b.i.d. treatment arms, sample sizes of 102:102:51:51, respectively, provided 94% power to detect a difference of 4 mm Hg in the change in mean DBP between the combination treatment and HCT, and 95% power to detect a difference of 5 mm Hg in the change in DBP between the combination therapy and either ramipril monotherapy. A dropout rate of approximately 15% was estimated during the treatment period. Thus, approximately 360 subjects were to be randomized across the 4 treatment groups to achieve approximately 306 completed subjects. The calculated sample size of 306 completed subjects was also adequate to assess the ambulatory BP data as planned, assuming a common standard deviation of 6 mm Hg and a two-sided significance level of a ¼ 0.05 for the power calculation. This sample size was to provide at least 97% power to detect a 4 mm Hg difference in the mean 24-h ambulatory DBP between both monotherapy treatment groups (25 mg HCT or 20 mg ramipril) and the combination treatment group.
The comparability of patients in the four treatment groups was determined from the demographic data and baseline BP values. The primary end points as well as all secondary continuous variables were analysed using an analysis of covariance model involving treatment group and study site, with baseline value as a covariate. Treatment group comparisons were based on the least square means obtained via the SAS general linear model procedure (SAS version 9.1.3; SAS Institute Inc., Cary, NC, USA). Effects of age, gender and ethnicity on end points were explored in subgroup analyses. Response rates for both clinic (proportion of patients achieving a clinic BP o135/85 mm Hg and proportion of patients achieving a clinic BP o140/ 90 mm Hg) and ambulatory (proportion of patients achieving at least an 8/5 mm Hg reduction in 24-h BP) monitoring were calculated and compared using the Cochran-Mantel-Haenszel test stratified by study site.
Results
Patient enrolment and disposition A total of 1004 patients were screened for the study of which 354 patients met the inclusion criteria and were randomized to the following treatment arms: 120 patients to ramipril-HCT, 57 patients to 20 mg ramipril, 56 patients to 10 mg ramipril b.i.d. and 121 patients to 25 mg HCT. A total of 285 of the 354 randomized patients completed the study as planned: (97 (81%) in the ramipril-HCT arm, 46 (81%) in the 20 mg ramipril arm, 48 (86%) in the 10 mg ramipril b.i.d. arm and 94 (78%) in the 25 mg HCT arm). The most common reasons for discontinuing the study early were lack of efficacy based on the judgment of the investigator (22 patients (6%)), withdrawal of consent (13 patients (4%)) and adverse events (15 patients (4%)).
Baseline characteristics of the study population
The baseline characteristics of all randomized patients in the four treatment arms are shown in Table 1 . For the entire patient population, the mean age was 51 years, a greater percentage of the population were men (55%), were predominantly non-black (66%) and with baseline clinic BPs of 157/103 mm Hg. Baseline characteristics were similar among the four treatment arms. Table 3 . A significantly larger proportion of patients receiving ramipril-HCT achieved both clinic and Clinic and 24-h ABPM in combination therapy WB White et al ambulatory BP goals compared to ramipril alone and HCT alone.
P<0.001 vs all monotherapies
Exploratory analyses to assess the impact of gender and ethnicity on blood pressure Age. The evaluation of the impact of age (o65 versus X65 years old) on reductions in BP was not possible in the trial as only 30 patients in the 4 treatment groups were over the age of 65 years.
Gender. There were 189 men and 152 women in the trial. Changes from baseline in the clinic BP in the ramipril-HCT treatment group were similar for men and women (À17.5/À15.1 mm Hg for men and À20.1/À16.8 mm Hg for women). In the 20 mg ramipril group, the mean changes from baseline for men were numerically greater than the changes from baseline for women, although this did not meet statistical significance (men, À12.8/À10.5 mm Hg; women, À8.0/À8.2 mm Hg). For the HCT group, the mean changes from baseline for women (À16.8/ À11.1 mm Hg) were significantly (Po0.001 for SBP and P ¼ 0.02 for DBP) greater than the changes from baseline observed in the men (À7.5/À6.4 mm Hg). Overall P-values testing the interaction between treatment group and gender showed that reductions between 20 mg ramipril daily and 25 mg HCT daily were statistically larger for men than that for women (P ¼ 0.0223 for DBP and 0.0052 for SBP).
Ethnicity group. There were 113 African Americans and 228 non-blacks in the trial. Changes from baseline in the clinic BP in the ramipril-HCT group were similar for both ethnic groups (À18.3/ À14.2 mm Hg for African Americans and À18.7/ À16.6 mm Hg for the non-blacks; P ¼ NS for both SBP and DBP). In the ramipril monotherapy groups, the changes from baseline were numerically larger in the non-black patients (10 mg ramipril b.i.d., Adverse events There were no deaths reported during the study. Of the 354 patients who were randomized in the study, a total of 163 (46%) had at least one adverse event with treatment during the 8-week double-blind Ambulatory blood pressure (76) 17 (47) 19 (54) 38 ( Table 4 . There were five patients who had a serious adverse event during the double-blind active treatment phase, and all discontinued prematurely from the trial. None of these events were determined to be drug-related by the investigator and they occurred in three of the four treatment groups (Table 4) . For the majority of laboratory studies, changes from baseline were not clinically meaningful in any of the four treatment groups. Changes from baseline in serum potassium were larger (À0.17 meq l À1 ) on HCT than those on ramipril-HCT (À0.03 meq l À1 ), 20 mg ramipril q.d. ( þ 0.08 meq l À1 ) and 10 mg ramipril b.i.d. ( þ 0.04 meq l À1 ). Blood urea nitrogen changes were larger ( þ 1.5 mg per 100 ml) on ramipril-HCT than those on ramipril (À1.2 to þ 0.3 mg per 100 ml) and HCT (0 mg per 100 ml). Serum uric acid levels decreased slightly on ramipril (À0.11 to À0.23 mg per 100 ml) and increased on ramipril-HCT ( þ 0.47 mg per 100 ml) and HCT ( þ 0.45 mg per 100 ml). The serum glucose levels increased from baseline in the ramipril-HCT group ( þ 5.4 mg per 100 ml) and HCT group ( þ 3.8 mg per 100 ml), and decreased from baseline in the 20 mg ramipril q.d. (À4.5 mg per 100 ml) and 10 mg ramipril b.i.d. (À4.8 mg per 100 ml) groups. None of these laboratory changes were thought to be clinically significant.
Discussion
Principal findings This large clinical trial using both semiautomated clinic BP and 24-h ambulatory BP recordings demonstrated that 20/25 mg ramipril-HCT lowered BP to a greater extent than ramipril and HCT monotherapies (Figures 1 and 2 and Tables 2 and  3 ). The findings were predictable, in part, considering the known benefits of stimulation of the reninangiotensin system with a diuretic and the addition of an ACE inhibitor. 16 Thus, the present study confirms that ramipril and HCT in the doses of 20 and 25 mg, respectively, are appropriate for the treatment of patients with stage 2 hypertension. Furthermore, the ramipril-HCT combination yielded results similar to some of the recent ambulatory BP trials for the angiotensin II receptor blockers that utilize the 25 mg dose of HCT, 17, 18 also an option that is useful in the management of clinical hypertension.
Effects of angiotensin converting enzyme inhibitors in combination with hydrochlorothiazide Several fixed-dose combination therapies of ACE inhibitors and diuretics are available for the treatment of hypertension. Initially, combinations with the ACE inhibitors were developed with HCT at a dose of 12.5 mg; these combinations typically showed additive effects on BP lowering regardless of which ACE inhibitor was studied. [16] [17] [18] More 18, 19 This treatment strategy was evaluated in our trial.
There have been few clinical trials of ramipril combined with HCT. These trials have used lower doses of the drugs than were used in the present study and assessed response with standard clinical measurements only. [20] [21] [22] In one of the earliest studies by the ATHES study group in France, 20 supine DBP was lowered to a greater extent by 2.5/12.5 mg ramipril-HCT q.d. than that by either monotherapy alone. Other investigators 21, 22 used doses of 5 or 10 mg ramipril combined with 12.5 and 25 mg HCT and also found as we did, that ramipril-HCT lowered BP by a greater extent than either component and with less potassium loss than HCT alone. The present study advances our understanding of the efficacy and safety of the combination of ramipril and HCT, as it evaluated higher doses and with more rigorous measurement techniques such as ABPM.
Importance of clinic versus ambulatory blood pressure measurements in the trial
The criterion for patient entry into the study was by clinic BP rather than by ambulatory BP values. Typically, ambulatory BP values-which usually are expressed as the average of all readings obtained over a 24-h period-are lower than clinic readings, largely because the ABPM data include nighttime values that, in most people, are substantially lower than daytime values. It has been calculated that to correspond with the clinic BP criterion of hypertension, usually 140/90 mm Hg or higher, the ambulatory 24-h average should be at least 130/ 85 mm Hg. 23, 24 Typically, the decreases in BP measured in the clinic are greater than those obtained by ambulatory recordings-this finding has been attributed to the fact that clinic BP measurements in clinical trials are more susceptible to regression to the mean, acclimation by the patient to the research environment and observer bias. 13, 23, 24 However, in the present study, changes from baseline in the clinic and ambulatory BP reductions were not quite as disparate as has been typically noted when the observer is using a mercury column or aneroid manometer to obtain the clinic BPs. Hence, we suspect that when clinic BPs are obtained by a semiautomatic device in triplicate, much, but not all, of the white-coat effect and/or observer bias is ameliorated.
It was also noteworthy that trends for the hypertension response rates were similar when measured by either clinic readings or ambulatory monitoring (Table 3) . For the clinic values, SBP and DBP were reduced below 140/90 mm Hg in 54% of patients receiving the ramipril-HCT combination therapy compared to ramipril monotherapy (24-27%) and HCT (23%). SBP and DBP were reduced below 135/85 mm Hg in 33% of patients receiving the ramipril-HCT combination therapy compared to ramipril monotherapy (13%) and HCT (12%). For the ABPM criteria, both SBP and DBP response rates were higher on the ramipril-HCT than those on the monotherapy groups. As these ABPM control rates are free of measurement bias, they indicate that this ACE inhibitor-based treatment regimen can produce the required treatment goals in a large proportion of patients.
Conclusion
The findings from the Ramipril-HCT Trial demonstrate that this combination is effective for the treatment of patients with stage 2 hypertension. Reductions in ambulatory BP are substantial and similar to maximal doses of angiotensin receptor blockers and thiazide diuretics. Furthermore, the subgroup analyses suggest that this combination is effective regardless of ethnicity or gender. Finally, adverse event rates for the combination therapy were similar to the known adverse event profiles of the individual agents.
